Swedish Orphan ADR (SWTUY) 14.1000 $SWTUY
New number of shares and votes in Swedish Orphan Biovitrum AB (publ)
Thomson Reuters ONE - Wed Sep 30, 1:01AM CDT
The total number of shares in Swedish Orphan Biovitrum AB (publ) as per 30 September 2015 amounts to 271,822,806 shares, whereof 270,389,770 common shares and 1,433,036 class C shares, corresponding to in total 270,533,073.6 votes. The increase in the number of shares and votes results from an issue of 1,036,856 class C shares under Swedish Orphan Biovitrum's incentive program. The class C shares are intended to ensure fulfillment of commitments under incentive programs. The company holds 2,763,768 common shares and all 1,433,036 class C shares.
Sobi CEO invests in 2015 LTI programme and divests a portion of incentive shares
Thomson Reuters ONE - Tue Sep 29, 1:01AM CDT
On 25 September Swedish Orphan Biovitrum AB (publ)'s (Sobi) CEO Geoffrey McDonough purchased 34,000 Sobi shares as part of the company's 2015 CEO long-term incentive programme. The programme requires that the CEO make an investment in common shares in Sobi for an amount of 4 MSEK which are subject to a 3 year lock-up period.
Biogen and Sobi receive positive opinion from CHMP for Elocta(TM) (rFVIIIFc) for the treatment of Haemophilia A
Thomson Reuters ONE - Fri Sep 25, 6:31AM CDT
Biogen (NASDAQ: BIIB) and Swedish Orphan Biovitrum AB (publ) (Sobi) (STO: SOBI) received a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for the marketing authorisation of Elocta(TM) (rFVIIIFc). Elocta is a recombinant factor VIII Fc fusion protein product for the treatment of haemophilia A that, if approved, would be the first haemophilia A treatment with prolonged circulation available in the European Union (EU).
BIIB: 269.16 (-10.72)
Selexis SA Announces Service Agreement with Swedish Orphan Biovitrum AB (Sobi)
PR Newswire - Tue Sep 22, 7:00AM CDT
Selexis SA, a serial innovation company with proven technologies for characterized mammalian Research Cell Banks (RCBs) used for drug discovery to commercial manufacturing, announced today the signing of a Service Agreement with Swedish Orphan Biovitrum AB (Sobi), a leading biopharmaceutical company focused developing therapies and services for people living with rare diseases.
Swedish Orphan Biovitrum AB (publ) : The board of directors exercises authorisation for repurchase of shares for the purpose of securing the company's commitments under the incentive programme
Thomson Reuters ONE - Fri Sep 11, 1:31AM CDT
The annual general meeting of Swedish Orphan Biovitrum AB (publ) on 30 June 2015 resolved - for the purpose of ensuring that the company can fulfil its commitments under the long-term incentive programme resolved by the annual general meeting - on a directed share issue of no more than 1,036,856 redeemable- and convertible class C shares.
FDA validates Orfadin(R) oral suspension filing
Thomson Reuters ONE - Thu Sep 10, 1:00AM CDT
Sobi (Swedish Orphan Biovitrum AB (publ)) today announced that the Food and Drug Administration (FDA) has initiated review of the oral suspension formulation of Orfadin (nitisinone) for the treatment of Hereditary Tyrosinaemia type-1 (HT-1). HT-1 is a rare genetic disease characterised by signs and symptoms that begin in the first few months of life. In affected infants the disease may result in liver and kidney failure, and can be fatal if not diagnosed and treated early in life.
Sobi opens European and Benelux office in Brussels
Thomson Reuters ONE - Tue Sep 08, 1:01AM CDT
Today Sobi (Swedish Orphan Biovitrum AB (publ)) formally opened its new European and Benelux office in Brussels, Belgium. The inauguration, celebrated today with a ribbon-cutting ceremony, results from Sobi's expanding international presence and further strengthens the company's platform in Europe as well as in the Benelux Region.
Sobi celebrates 25 years with Orfadin(R) (nitisinone) - a result of ground-breaking Swedish research
Thomson Reuters ONE - Fri Sep 04, 1:00AM CDT
To acknowledge that it is 25 years since the first person with the rare genetic disease Hereditary Tyrosinaemia type 1 (HT-1) was treated in clinical trials with Orfadin(R) (nitisinone), Swedish Orphan Biovitrum AB (publ) (Sobi) (STO: SOBI) hosted a satellite symposium in Lyon, France in conjunction with the annual SSIEM symposium, Society for the Study of Inborn Errors of Metabolism. HT-1 is a progressive disease that affects infants and children, may result in liver and kidney failure and can be fatal if it is not diagnosed and treated early in life.
Kineret(R) receives Australian regulatory approval for use in Systemic Juvenile Idiopathic Arthritis
Thomson Reuters ONE - Wed Aug 19, 3:31AM CDT
Swedish Orphan Biovitrum AB (publ) (Sobi) together with its Australian partner, A. Menarini Australia Pty Ltd received marketing authorisation in Australia for Kineret (anakinra) for the treatment of systemic juvenile idiopathic arthritis (SJIA), which is a rare form of juvenile chronic arthritis.
Results from B-YOND study reinforce long-term clinical profile of Alprolix for the treatment of haemophilia B
Thomson Reuters ONE - Tue Aug 18, 3:02AM CDT
Swedish Orphan Biovitrum AB (publ) (Sobi) (STO: SOBI) and its partner Biogen released interim results from the B-YOND study presented at the 67th Annual Meeting for the National Hemophilia Foundation in Dallas, Texas. The results support the long-term safety and efficacy of Alprolix(R) (rFIXFc) in people with severe haemophilia B treated for up to two years. Participants in this phase 3, open-label long-term study maintained low bleeding rates with one to two week prophylaxis regimens. No inhibitors have been reported to-date.
Extension study data supporting long-term safety and efficacy of Eloctate(R)/Elocta(R) published in Haemophilia
Thomson Reuters ONE - Mon Aug 10, 6:02AM CDT
- Interim results show participants maintained low bleeding rates with prophylactic dosing
BIIB: 269.16 (-10.72)
Global Dysphagia Clinical Trials Review, H1, 2015
M2 - Wed Aug 05, 6:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w2jppd/dysphagia_global) has announced the addition of the "Dysphagia Global Clinical Trials Review, H1, 2015" report to their offering. Dysphagia Global Clinical Trials Review, H1, 2015 provides data on the Dysphagia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Dysphagia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Dysphagia. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - Swedish Orphan Biovitrum AB Clinical Trial Overview of Top Institutes / Government - The University of Tokushima - Department of Health, South Africa - Hillel Yaffe Medical Center - Hospital de Mataro - Shanghai Changzheng Hospital - University of Arkansas - University of California, Davis - Winthrop-University Hospital - Aarhus University - Ain Shams University For more information visit http://www.researchandmarkets.com/research/w2...gia_global
Sobi publishes its Report for the Second Quarter 2015 - raises guidance
Thomson Reuters ONE - Thu Jul 16, 1:01AM CDT
Swedish Orphan Biovitrum AB (publ) (Sobi) today announced its results for the second quarter 2015. Revenues for the quarter totalled SEK 764 M (663), an increase of 15 per cent year-on year. The product portfolio grew 25 per cent with Orfadin(R) and Kineret(R) delivering strong performance.
Sobi exercises opt-in right for Alprolix(R)
Thomson Reuters ONE - Thu Jul 16, 1:00AM CDT
Swedish Orphan Biovitrum AB (publ) (Sobi) (STO: SOBI) announced today that the company has decided to exercise its opt-in right to take over final development and commercialisation of Alprolix (rFIXFc) for the territory composed of Europe, North Africa, Russia and certain Middle Eastern markets. Alprolix is a recombinant factor IX Fc fusion protein product candidate for the treatment of haemophilia B. Sobi will make a payment to Biogen of USD 10 million, which will be held in escrow pending the EU regulatory approval of Alprolix.
Psoriatic Arthritis Pipeline Report 2015 - 28 Companies & 25 Drug Profiles
M2 - Fri Jul 10, 3:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/s9fbkq/psoriatic) has announced the addition of the "Psoriatic Arthritis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Psoriatic Arthritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Psoriatic Arthritis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - AbGenomics International, Inc. - Alder Biopharmaceuticals Inc. - Amgen Inc. - Avesthagen Limited - Biocon Limited - Bristol-Myers Squibb Company - Celgene Corporation - Celltrion, Inc. - Coherus BioSciences, Inc. - Covagen AG - Eli Lilly and Company - Epirus Biopharmaceuticals, Inc. - Genor BioPharma Co., Ltd. - Inbiopro Solutions Pvt. Ltd. - Innovent Biologics, Inc. - Johnson & Johnson - Kineta, Inc. - Mabion SA - Momenta Pharmaceuticals, Inc. - Novartis AG - Oncobiologics, Inc. - Panacea Biotec Limited - Pfizer Inc. - Sandoz International GmbH - Swedish Orphan Biovitrum AB - Therapeutic Proteins International, LLC - UCB S.A. Drug Profiles - abatacept (recombinant) - AbGn-168H - ABT-122 - adalimumab biosimilar - anakinra (recombinant) - apremilast - bimekizumab - brodalumab - clazakizumab - COVA-322 - dalazatide - etanercept biosimilar - golimumab - golimumab biosimilar - guselkumab - IBI-303 - IBPM-004AM - IBPM-005IX - infliximab biosimilar - INV-17 - itolizumab - ixekizumab - Peptide to Inhibit CD44 for Rheumatoid and Psoriatic Arthritis - secukinumab - tofacitinib For more information visit http://www.researchandmarkets.com/research/s9fbkq/psoriatic
PFE: 33.24 (+0.15), AMGN: 149.59 (-0.31), LLY: 86.14 (+2.37), BMY: 61.44 (+0.93), MNTA: 16.54 (-0.18), CHRS: 23.29 (-0.07), JNJ: 95.37 (+0.29), ALDR: 28.80 (-0.56), ABBV: 55.64 (-0.40), NVS: 91.90 (-0.71), CELGZ: 1.74 (+0.04)
Psoriatic Arthritis Therapeutic Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com
PRWeb - Thu Jul 09, 8:30PM CDT
The report "Psoriatic Arthritis - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Psoriatic Arthritis. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/psoriatic-ar...eport.html .
JNJ: 95.37 (+0.29), ALDR: 28.80 (-0.56), PFE: 33.24 (+0.15), AMGN: 149.59 (-0.31), LLY: 86.14 (+2.37), BMY: 61.44 (+0.93), NVS: 91.90 (-0.71), CHRS: 23.29 (-0.07), CELGZ: 1.74 (+0.04)
Resolutions from Sobi's Annual General Meeting
Thomson Reuters ONE - Tue Jun 30, 9:16AM CDT
The Swedish Orphan Biovitrum AB (publ) (Sobi) Annual General Meeting (AGM) convened earlier today in Stockholm and voted in favour of the resolutions proposed at the meeting, including:
European Commission approves Orfadin(R) oral suspension
Thomson Reuters ONE - Mon Jun 29, 1:00AM CDT
Swedish Orphan Biovitrum AB (publ) (Sobi) today announced that the European Commission has approved the oral suspension formulation of Orfadin(R) (nitisinone) for the treatment of Hereditary Tyrosinaemia type-1 (HT-1) as of 19 June 2015. HT-1 is a rare genetic disease that affects infants and children. It is progressive and may result in liver and kidney failure and can be fatal if untreated.
Invitation - Presentation of Sobi's second quarter 2015
Thomson Reuters ONE - Fri Jun 26, 1:30AM CDT
On 16 July, at 08:00 CET, Swedish Orphan Biovitrum AB (publ) (Sobi) will publish its report for the second quarter 2015.
Sobi's 2012 Long-Term Incentive programme meets all objectives
Thomson Reuters ONE - Fri Jun 12, 1:00AM CDT
Swedish Orphan Biovitrum AB's (publ) (Sobi) Board of Directors today announced that the company's 2012 Long-Term Incentive programme met the objectives set and has vested in full. The total number of shares awarded to Sobi employees enrolled in the 2012 programme is 583,139.
New number of shares and votes in Swedish Orphan Biovitrum AB (publ)
Thomson Reuters ONE - Wed Sep 30, 1:01AM CDT
The total number of shares in Swedish Orphan Biovitrum AB (publ) as per 30 September 2015 amounts to 271,822,806 shares, whereof 270,389,770 common shares and 1,433,036 class C shares, corresponding to in total 270,533,073.6 votes. The increase in the number of shares and votes results from an issue of 1,036,856 class C shares under Swedish Orphan Biovitrum's incentive program. The class C shares are intended to ensure fulfillment of commitments under incentive programs. The company holds 2,763,768 common shares and all 1,433,036 class C shares.
Sobi CEO invests in 2015 LTI programme and divests a portion of incentive shares
Thomson Reuters ONE - Tue Sep 29, 1:01AM CDT
On 25 September Swedish Orphan Biovitrum AB (publ)'s (Sobi) CEO Geoffrey McDonough purchased 34,000 Sobi shares as part of the company's 2015 CEO long-term incentive programme. The programme requires that the CEO make an investment in common shares in Sobi for an amount of 4 MSEK which are subject to a 3 year lock-up period.
Biogen and Sobi receive positive opinion from CHMP for Elocta(TM) (rFVIIIFc) for the treatment of Haemophilia A
Thomson Reuters ONE - Fri Sep 25, 6:31AM CDT
Biogen (NASDAQ: BIIB) and Swedish Orphan Biovitrum AB (publ) (Sobi) (STO: SOBI) received a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for the marketing authorisation of Elocta(TM) (rFVIIIFc). Elocta is a recombinant factor VIII Fc fusion protein product for the treatment of haemophilia A that, if approved, would be the first haemophilia A treatment with prolonged circulation available in the European Union (EU).
BIIB: 269.16 (-10.72)
Selexis SA Announces Service Agreement with Swedish Orphan Biovitrum AB (Sobi)
PR Newswire - Tue Sep 22, 7:00AM CDT
Selexis SA, a serial innovation company with proven technologies for characterized mammalian Research Cell Banks (RCBs) used for drug discovery to commercial manufacturing, announced today the signing of a Service Agreement with Swedish Orphan Biovitrum AB (Sobi), a leading biopharmaceutical company focused developing therapies and services for people living with rare diseases.
Swedish Orphan Biovitrum AB (publ) : The board of directors exercises authorisation for repurchase of shares for the purpose of securing the company's commitments under the incentive programme
Thomson Reuters ONE - Fri Sep 11, 1:31AM CDT
The annual general meeting of Swedish Orphan Biovitrum AB (publ) on 30 June 2015 resolved - for the purpose of ensuring that the company can fulfil its commitments under the long-term incentive programme resolved by the annual general meeting - on a directed share issue of no more than 1,036,856 redeemable- and convertible class C shares.
FDA validates Orfadin(R) oral suspension filing
Thomson Reuters ONE - Thu Sep 10, 1:00AM CDT
Sobi (Swedish Orphan Biovitrum AB (publ)) today announced that the Food and Drug Administration (FDA) has initiated review of the oral suspension formulation of Orfadin (nitisinone) for the treatment of Hereditary Tyrosinaemia type-1 (HT-1). HT-1 is a rare genetic disease characterised by signs and symptoms that begin in the first few months of life. In affected infants the disease may result in liver and kidney failure, and can be fatal if not diagnosed and treated early in life.
Sobi opens European and Benelux office in Brussels
Thomson Reuters ONE - Tue Sep 08, 1:01AM CDT
Today Sobi (Swedish Orphan Biovitrum AB (publ)) formally opened its new European and Benelux office in Brussels, Belgium. The inauguration, celebrated today with a ribbon-cutting ceremony, results from Sobi's expanding international presence and further strengthens the company's platform in Europe as well as in the Benelux Region.
Sobi celebrates 25 years with Orfadin(R) (nitisinone) - a result of ground-breaking Swedish research
Thomson Reuters ONE - Fri Sep 04, 1:00AM CDT
To acknowledge that it is 25 years since the first person with the rare genetic disease Hereditary Tyrosinaemia type 1 (HT-1) was treated in clinical trials with Orfadin(R) (nitisinone), Swedish Orphan Biovitrum AB (publ) (Sobi) (STO: SOBI) hosted a satellite symposium in Lyon, France in conjunction with the annual SSIEM symposium, Society for the Study of Inborn Errors of Metabolism. HT-1 is a progressive disease that affects infants and children, may result in liver and kidney failure and can be fatal if it is not diagnosed and treated early in life.
Kineret(R) receives Australian regulatory approval for use in Systemic Juvenile Idiopathic Arthritis
Thomson Reuters ONE - Wed Aug 19, 3:31AM CDT
Swedish Orphan Biovitrum AB (publ) (Sobi) together with its Australian partner, A. Menarini Australia Pty Ltd received marketing authorisation in Australia for Kineret (anakinra) for the treatment of systemic juvenile idiopathic arthritis (SJIA), which is a rare form of juvenile chronic arthritis.
Results from B-YOND study reinforce long-term clinical profile of Alprolix for the treatment of haemophilia B
Thomson Reuters ONE - Tue Aug 18, 3:02AM CDT
Swedish Orphan Biovitrum AB (publ) (Sobi) (STO: SOBI) and its partner Biogen released interim results from the B-YOND study presented at the 67th Annual Meeting for the National Hemophilia Foundation in Dallas, Texas. The results support the long-term safety and efficacy of Alprolix(R) (rFIXFc) in people with severe haemophilia B treated for up to two years. Participants in this phase 3, open-label long-term study maintained low bleeding rates with one to two week prophylaxis regimens. No inhibitors have been reported to-date.
Extension study data supporting long-term safety and efficacy of Eloctate(R)/Elocta(R) published in Haemophilia
Thomson Reuters ONE - Mon Aug 10, 6:02AM CDT
- Interim results show participants maintained low bleeding rates with prophylactic dosing
BIIB: 269.16 (-10.72)
Global Dysphagia Clinical Trials Review, H1, 2015
M2 - Wed Aug 05, 6:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w2jppd/dysphagia_global) has announced the addition of the "Dysphagia Global Clinical Trials Review, H1, 2015" report to their offering. Dysphagia Global Clinical Trials Review, H1, 2015 provides data on the Dysphagia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Dysphagia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Dysphagia. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - Swedish Orphan Biovitrum AB Clinical Trial Overview of Top Institutes / Government - The University of Tokushima - Department of Health, South Africa - Hillel Yaffe Medical Center - Hospital de Mataro - Shanghai Changzheng Hospital - University of Arkansas - University of California, Davis - Winthrop-University Hospital - Aarhus University - Ain Shams University For more information visit http://www.researchandmarkets.com/research/w2...gia_global
Sobi publishes its Report for the Second Quarter 2015 - raises guidance
Thomson Reuters ONE - Thu Jul 16, 1:01AM CDT
Swedish Orphan Biovitrum AB (publ) (Sobi) today announced its results for the second quarter 2015. Revenues for the quarter totalled SEK 764 M (663), an increase of 15 per cent year-on year. The product portfolio grew 25 per cent with Orfadin(R) and Kineret(R) delivering strong performance.
Sobi exercises opt-in right for Alprolix(R)
Thomson Reuters ONE - Thu Jul 16, 1:00AM CDT
Swedish Orphan Biovitrum AB (publ) (Sobi) (STO: SOBI) announced today that the company has decided to exercise its opt-in right to take over final development and commercialisation of Alprolix (rFIXFc) for the territory composed of Europe, North Africa, Russia and certain Middle Eastern markets. Alprolix is a recombinant factor IX Fc fusion protein product candidate for the treatment of haemophilia B. Sobi will make a payment to Biogen of USD 10 million, which will be held in escrow pending the EU regulatory approval of Alprolix.
Psoriatic Arthritis Pipeline Report 2015 - 28 Companies & 25 Drug Profiles
M2 - Fri Jul 10, 3:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/s9fbkq/psoriatic) has announced the addition of the "Psoriatic Arthritis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Psoriatic Arthritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Psoriatic Arthritis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - AbGenomics International, Inc. - Alder Biopharmaceuticals Inc. - Amgen Inc. - Avesthagen Limited - Biocon Limited - Bristol-Myers Squibb Company - Celgene Corporation - Celltrion, Inc. - Coherus BioSciences, Inc. - Covagen AG - Eli Lilly and Company - Epirus Biopharmaceuticals, Inc. - Genor BioPharma Co., Ltd. - Inbiopro Solutions Pvt. Ltd. - Innovent Biologics, Inc. - Johnson & Johnson - Kineta, Inc. - Mabion SA - Momenta Pharmaceuticals, Inc. - Novartis AG - Oncobiologics, Inc. - Panacea Biotec Limited - Pfizer Inc. - Sandoz International GmbH - Swedish Orphan Biovitrum AB - Therapeutic Proteins International, LLC - UCB S.A. Drug Profiles - abatacept (recombinant) - AbGn-168H - ABT-122 - adalimumab biosimilar - anakinra (recombinant) - apremilast - bimekizumab - brodalumab - clazakizumab - COVA-322 - dalazatide - etanercept biosimilar - golimumab - golimumab biosimilar - guselkumab - IBI-303 - IBPM-004AM - IBPM-005IX - infliximab biosimilar - INV-17 - itolizumab - ixekizumab - Peptide to Inhibit CD44 for Rheumatoid and Psoriatic Arthritis - secukinumab - tofacitinib For more information visit http://www.researchandmarkets.com/research/s9fbkq/psoriatic
PFE: 33.24 (+0.15), AMGN: 149.59 (-0.31), LLY: 86.14 (+2.37), BMY: 61.44 (+0.93), MNTA: 16.54 (-0.18), CHRS: 23.29 (-0.07), JNJ: 95.37 (+0.29), ALDR: 28.80 (-0.56), ABBV: 55.64 (-0.40), NVS: 91.90 (-0.71), CELGZ: 1.74 (+0.04)
Psoriatic Arthritis Therapeutic Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com
PRWeb - Thu Jul 09, 8:30PM CDT
The report "Psoriatic Arthritis - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Psoriatic Arthritis. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/psoriatic-ar...eport.html .
JNJ: 95.37 (+0.29), ALDR: 28.80 (-0.56), PFE: 33.24 (+0.15), AMGN: 149.59 (-0.31), LLY: 86.14 (+2.37), BMY: 61.44 (+0.93), NVS: 91.90 (-0.71), CHRS: 23.29 (-0.07), CELGZ: 1.74 (+0.04)
Resolutions from Sobi's Annual General Meeting
Thomson Reuters ONE - Tue Jun 30, 9:16AM CDT
The Swedish Orphan Biovitrum AB (publ) (Sobi) Annual General Meeting (AGM) convened earlier today in Stockholm and voted in favour of the resolutions proposed at the meeting, including:
European Commission approves Orfadin(R) oral suspension
Thomson Reuters ONE - Mon Jun 29, 1:00AM CDT
Swedish Orphan Biovitrum AB (publ) (Sobi) today announced that the European Commission has approved the oral suspension formulation of Orfadin(R) (nitisinone) for the treatment of Hereditary Tyrosinaemia type-1 (HT-1) as of 19 June 2015. HT-1 is a rare genetic disease that affects infants and children. It is progressive and may result in liver and kidney failure and can be fatal if untreated.
Invitation - Presentation of Sobi's second quarter 2015
Thomson Reuters ONE - Fri Jun 26, 1:30AM CDT
On 16 July, at 08:00 CET, Swedish Orphan Biovitrum AB (publ) (Sobi) will publish its report for the second quarter 2015.
Sobi's 2012 Long-Term Incentive programme meets all objectives
Thomson Reuters ONE - Fri Jun 12, 1:00AM CDT
Swedish Orphan Biovitrum AB's (publ) (Sobi) Board of Directors today announced that the company's 2012 Long-Term Incentive programme met the objectives set and has vested in full. The total number of shares awarded to Sobi employees enrolled in the 2012 programme is 583,139.
